SLP

Simulations Plus, Inc.

39.35 USD

Last updated Dec 10, 08:17 UTC

Yesterday HIGH

$39.75

Yesterday LOW

$38.95

52w HIGH

$52.69

52w LOW

$32.58

EPS

0.18

PE

218.61

Next Earnings

Jan 3, 2024

Overview News Insider Transactions Government Trades

Simulations Plus, Inc. stock is up 10.35% since 30 days ago. The next earnings date is Jan 3, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 51.85% of the previous 26 December’s closed higher than November.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym; IPFsym; RENAsym; MITOsym.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Computer Software

Headquarters

Lan, United States Of America

Website

simulations-plus.com

Lisa Levin

Fri Apr 28, 2023

Roblox And 3 Other Stocks Insiders Are Selling

The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades.
Benzinga Newsdesk

Tue Apr 18, 2023

Simulations Plus Receives FDA Renewal For DILIsym Software Licenses
richadhand@benzinga.com

Thu Apr 6, 2023

Oppenheimer Reiterates Outperform on Simulations Plus, Maintains $65 Price Target

Oppenheimer analyst Francois Brisebois reiterates Simulations Plus (NASDAQ:SLP) with a Outperform and maintains $65 price target.
Benzinga Newsdesk

Wed Apr 5, 2023

Simulations Plus Maintains Full-Year Guidance

Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS Guidance of $0.63 - $0.67
Benzinga Newsdesk

Wed Apr 5, 2023

Simulations Plus Q2 EPS $0.20 Beats $0.18 Estimate, Sales $15.75M Miss $16.13M Estimate

Simulations Plus (NASDAQ:SLP) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.18 by 11.11 percent. This is a 4.76 percent decrease over earnings of $0.21 per share from the
Benzinga Insights

Wed Apr 5, 2023

Earnings Scheduled For April 5, 2023

Companies Reporting Before The Bell • Seadrill (NYSE:SDRL) is projected to report earnings for its fourth quarter.
Benzinga Insights

Tue Apr 4, 2023

Preview: Simulations Plus's Earnings
Happy Mohamed

Tue Mar 28, 2023

Simulations Plus Enters New Strategic Collaboration To Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology

Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling
Happy Mohamed

Wed Mar 15, 2023

Simulations Plus Enters Partnership To Apply AI/ML Technologies To Design Novel Compounds

Promising intellectual property resulting from the collaboration with Polish Academy of Sciences will be jointly owned for further development opportunities Simulations Plus, Inc. (NASDAQ:SLP), a leading provider
Benzinga Newsdesk

Thu Jan 12, 2023

Reported Late Wednesday, Simulations Plus Executes $20M Accelerated Share Repurchase Agreement; The ASR Agreement Is Part Of The $50M Share Repurchase Program Authorized By The Board Of Directors On December 29, 2022

Initiates first steps in updated capital allocation strategy Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today

WOLTOSZ WALTER S, Director

Fri Dec 1, 2023

SLP Recent Insider Trades and Stock Chart

31,148 shares sold
WOLTOSZ WALTER S, Director

Mon Dec 4, 2023

SLP Recent Insider Trades and Stock Chart

21,802 shares sold
WOLTOSZ WALTER S, Director

Tue Dec 5, 2023

SLP Recent Insider Trades and Stock Chart

7,050 shares sold